By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Pathology said today that it is collaborating with research hospitals in Toronto that will use its proteomic analysis tools in studies aimed at developing an assay that could be used to identify patients that are most likely to respond to anti-epidermal growth factor receptor (EGFR) drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.